Meta-Analysis: Do GLP-1 Drugs Improve Heart Risk Factors in Type 1 Diabetes Too? | Research

The takeaway

A systematic review and meta-analysis of RCTs evaluates GLP-1 receptor agonists as adjunctive therapy for cardiometabolic risk factors in type 1 diabetes, extending research beyond their established type 2 diabetes benefits.

T1DM cardiometabolic effects assessed
First comprehensive meta-analysis of GLP-1 RA benefits in type 1 diabetes

What the researchers found

The meta-analysis evaluated GLP-1RA adjunctive therapy effects on cardiometabolic risk factors in T1DM across available RCTs, extending evidence beyond the established T2DM indications.

Why it matters

Type 1 diabetes patients also face elevated cardiovascular risk. If GLP-1 drugs provide cardiometabolic benefits in T1DM, millions of additional patients could benefit.

How the study worked

Systematic review and meta-analysis of RCTs from PubMed, Embase, Cochrane Library, and Web of Science through August 2025; PRISMA methodology.

What this study cannot tell us

Likely few available RCTs in T1DM; studies may be small and heterogeneous; GLP-1 drugs are not approved for T1DM; hypoglycemia risk with insulin combination.

How to read the evidence

Systematic review and meta-analysis of RCTs — highest evidence synthesis, though limited by available T1DM trial data.

When this study was published

Published in 2026 with evidence through August 2025, providing the most current data on GLP-1 drugs in type 1 diabetes.

The bigger picture

This explores whether GLP-1 drugs' benefits extend across diabetes types — which could fundamentally change type 1 diabetes management from pure glucose control to comprehensive cardiometabolic risk reduction.

Questions still open

Should GLP-1 drugs be considered for overweight type 1 diabetes patients specifically?
Do cardiometabolic benefits in T1DM translate to reduced cardiovascular events long-term?

Common questions

Can people with type 1 diabetes take GLP-1 drugs?

GLP-1 drugs are not currently approved for type 1 diabetes, but some doctors prescribe them off-label. This meta-analysis examines whether they provide cardiometabolic benefits in T1DM beyond what insulin alone achieves.

How is type 1 diabetes different for heart risk?

T1DM patients face 2-3 times higher cardiovascular risk than the general population, driven by factors beyond blood sugar. If GLP-1 drugs improve weight, blood pressure, and lipids in T1DM, they could help reduce this excess risk.

Read the original research

Effect of Glucagon-Like Peptide-1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Diabetes/metabolism research and reviews, 42(1), e70111

View on PubMed ↗Publisher’s paper ↗

Citation

Chen, Yizhu; Tang, Yufei; Yue, Rui; Yang, Bo; Wang, Ai; Long, Yang; Xu, Yong; Gao, Chenlin. (2026). Effect of Glucagon-Like Peptide-1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.. Diabetes/metabolism research and reviews, 42(1), e70111. https://doi.org/10.1002/dmrr.70111